Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adoptive Immunotherapy for Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cells

NCT03720496 is registered in ClinicalTrials.gov with Timmune Biotech Inc. as lead sponsor.

NCT NCT03720496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03720496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adoptive Immunotherapy for Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cells
Lead sponsor
Timmune Biotech Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
November 1, 2018
Completion date
December 1, 2021
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma,b cell